This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Oliphant, C. M. Articles by Bonnema, S. M. Search for Related Content Social Bookmarking                   What's this?

New Advances in the Pharmacological Treatment of Human Immunodeficiency Virus (HIV) Infection: Focus on Protease Inhibitors

Scott M. Bonnema

The introduction of a new class of anti-HIV agents, the protease inhibitors, has given new hope to patients with HIV infection. Use of these agents requires the pharmacist to have a complete knowledge of phar macokinetics, adverse reactions, drug-drug interactions, and resistance profiles. Patient compliance is one of the most important factors affecting the success and failure of protease inhibitor therapy. Pharma cists have the opportunity to positively influence outcomes of HIV therapy.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?